Abstract: PAPP-A2 is used as a marker for monitoring, predicting and diagnosing preeclampsia in pregnant women. PAPP-A2 levels in pregnant women with preeclampsia are higher than PAPP-A2 levels in normal pregnant women. This is especially true of PAPP-A2 levels that are measured later on in the pregnancy. PAPP-A2 levels may be measured early in pregnancy in order to predict the likelihood of the patient having preeclampsia. Preeclampsia may also be diagnosed at later gestational ages when the levels of PAPP-A2 are more pronounced than normal PAPP-A2 levels at the same gestational age. The present invention relates to methods of assessing, predicting and diagnosing preeclampsia as well as a kit-of-parts for assessing, predicting and diagnosing preeclampsia.